Human immunodeficiency virus-associated multicentric Castleman disease refractory to antiretroviral therapy: clinical features, treatment and outcome

References

• Castleman B, Towne VW. Case records of the Massachusetts General Hospital: Case No. 40231. N Engl J Med 1954;250:1001–1005.
   PubMedGoogle Scholar
• Kim B, Jeon YK, Kim CW. Kaposi sarcoma herpes virus-associated hemophagocytic syndrome complicated by multicentric castleman disease and kaposi sarcoma in a HIV-negative immunocompetent patient: an autopsy case. J Korean Med Sci 2009;24:970–974.
   PubMed Web of Science ®Google Scholar
• Seo HY, Kim EB, Kim JW, et al. Complete remission in a patient with human herpes virus-8 negative multicentric Castleman disease using CHOP chemotherapy. Cancer Res Treat 2009;41:104–107.
   PubMedGoogle Scholar
• Powles T, Stebbing J, Bazeos A, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Ann Oncol 2009;20:775–779.
   PubMed Web of Science ®Google Scholar
• Bower M. How I treat HIV-associated multicentric Castleman disease. Blood 2010;116:4415–4421.
   PubMed Web of Science ®Google Scholar
• Mylona EE, Baraboutis IG, Lekakis LJ, et al. Multicentric Castleman's disease in HIV infection: a systematic review of the literature. AIDS Rev 2008;10:25–35.
   PubMed Web of Science ®Google Scholar
• Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 2002;99:2331–2336.
   PubMed Web of Science ®Google Scholar
• Cattaneo C, Vaccher E, Re A, et al. HAART does not improve the outcome of HIV-related multicentric Castleman disease: results of a multicentric retrospective study. Blood 2011;118(Suppl. 1): Abstract 4918.
   Google Scholar
• Mylona EE, Baraboutis IG, Lekakis LJ, et al. Multicentric Castleman's disease in HIV infection: a systematic review of the literature. AIDS Rev 2008;10:25–35.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106:2627–2632.
   PubMed Web of Science ®Google Scholar
• Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV- 8-positive plasmablastic lymphoma. Blood 2000;95:1406–1412.
   PubMed Web of Science ®Google Scholar
• Sunil M, Reid E, Lechowicz MJ. Update on HHV-8-associated malignancies. Curr Infect Dis Rep 2010;12:147–154.
   PubMedGoogle Scholar
• Bower M, Veraitch O, Szydlo R, et al. Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease. Blood 2009;113:4521–4524.
   PubMed Web of Science ®Google Scholar
• Uldrick TS, Wang V, O’Mahony D, et al. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. Clin Infect Dis 2010;51:350–358.
   PubMed Web of Science ®Google Scholar
• Chen CH, Liu HC, Hung TT, et al. Possible roles of Epstein-Barr virus in Castleman disease. J Cardiothorac Surg 2009;4:31.
   PubMed Web of Science ®Google Scholar
• Casper C, Krantz EM, Corey L, et al. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial. J Infect Dis 2008;198:23–30.
   PubMed Web of Science ®Google Scholar
• Talarico F, Negri L, Iusco D, et al. Unicentric Castleman's disease in peripancreatic tissue: case report and review of the literature. G Chir 2008;29:141–144.
   PubMedGoogle Scholar
• Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman's disease: a systematic review of 404 published cases. Ann Surg 2012;255:677–684.
   PubMed Web of Science ®Google Scholar
• Casper C, Nichols WG, Huang ML, et al. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 2004;103:1632–1634.
   PubMed Web of Science ®Google Scholar
• Berezne A, Agbalika F, Oksenhendler E. Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood 2004; 103:4368–4369; author reply 4369.
   Google Scholar
• Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 2001;98:3473–3475.
   PubMed Web of Science ®Google Scholar
• Senanayake S, Kelly J, Lloyd A, et al. Multicentric Castleman's disease treated with antivirals and immunosuppressants. J Med Virol 2003;71:399–403.
   PubMed Web of Science ®Google Scholar
• Scott D, Cabral L, Harrington WJ Jr. Treatment of HIV-associated multicentric Castleman's disease with oral etoposide. Am J Hematol 2001;66:148–150.
   PubMed Web of Science ®Google Scholar
• Chronowski GM, Ha CS, Wilder RB, et al. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 2001;92:670–676.
   PubMed Web of Science ®Google Scholar
• Herrada J, Cabanillas F, Rice L, et al. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 1998;128:657–662.
   PubMed Web of Science ®Google Scholar
• Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med 2007;147:836–839.
   PubMed Web of Science ®Google Scholar
• Gerard L, Berezne A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol 2007;25:3350–3356.
   PubMed Web of Science ®Google Scholar
• Kim B, Jeon YK, Kim CW. Kaposi sarcoma herpes virus-associated hemophagocytic syndrome complicated by multicentric castleman disease and kaposi sarcoma in a HIV-negative immunocompetent patient: an autopsy case. J Korean Med Sci 2009;24:970–974.
   PubMed Web of Science ®Google Scholar
• Marcelin AG, Aaron L, Mateus C, et al. Rituximab therapy for HIV-associated Castleman disease. Blood 2003;102:2786–2788.
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Schmid H, Muller M, et al. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood 2011;118:3499–3503.
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937–951.
   PubMed Web of Science ®Google Scholar
• Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124–131.
   PubMed Web of Science ®Google Scholar
• Mills JA, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schonlein purpura. Arthritis Rheum 1990;33:1114–1121.
   PubMed Web of Science ®Google Scholar
• Lexi-Comp Online™ Interaction Lookup. Available from: www.uptodate.com/contents/search
   Google Scholar
• Chemotherapy protocols, lymphoma & myeloma. Available from: www.bccancer.bc.ca/HPI/ChemotherapyProtocols/derault.htm
   Google Scholar
• Al-Salamah SM, Khan IA, Khalid K, et al. Castleman disease presenting as obstructive jaundice. Saudi Med J 2005;26:111–113.
   PubMed Web of Science ®Google Scholar
• Park JB, Hwang JH, Kim H, et al. Castleman disease presenting with jaundice: a case with the multicentric hyaline vascular variant. Korean J Intern Med 2007;22:113–117.
   PubMedGoogle Scholar
• Przkora R, Bruns C, Zulke C, et al. Castleman's disease causing obstructive jaundice. J Hepatol. 2003;38:548–549.
   PubMed Web of Science ®Google Scholar
• Venkataraman G, Uldrick TS, Aleman K, et al. Bone marrow findings in HIV-positive patients with Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Am J Clin Pathol 2013; 139:651–661.
   PubMed Web of Science ®Google Scholar
• Lin L, Lee JY, Kaplan LD, et al. Effects of chemotherapy in AIDS-associated non-Hodgkin's lymphoma on Kaposi's sarcoma herpesvirus DNA in blood. J Clin Oncol 2009;27:2496–2502.
   PubMed Web of Science ®Google Scholar
• Tedeschi R, Marus A, Bidoli E, et al. Human herpesvirus 8 DNA quantification in matched plasma and PBMCs samples of patients with HHV8-related lymphoproliferative diseases. J Clin Virol 2008;43:255–259.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Adams C, Sanitt A, et al. Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease. Blood 2011;118:271–275.
   PubMedGoogle Scholar
• Miyagi T, Nagasaki A, Taira T, et al. [A Japanese case of human herpes virus-8-associated multicentric castleman disease complicated by hemophagocytic syndrome]. Gan To Kagaku Ryoho 2008;35: 1431–1434.
   PubMedGoogle Scholar
• Yates JA, Zakai NA, Griffith RC, et al. Multicentric Castleman disease, Kaposi sarcoma, hemophagocytic syndrome, and a novel HHV8-lymphoproliferative disorder. AIDS Read 2007;17:596–598, 601.
   PubMed Web of Science ®Google Scholar
• Lee KD, Lee KW, Choi IS, et al. Multicentric Castleman's disease complicated by tumor lysis syndrome. Ann Hematol 2004; 83:722–725.
   PubMed Web of Science ®Google Scholar